307 related articles for article (PubMed ID: 27825958)
1. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
2. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
[TBL] [Abstract][Full Text] [Related]
3. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway.
Nitta RT; Gholamin S; Feroze AH; Agarwal M; Cheshier SH; Mitra SS; Li G
Oncogene; 2015 Jul; 34(28):3688-99. PubMed ID: 25241897
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
[TBL] [Abstract][Full Text] [Related]
10. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
11. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
12. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
Qi Q; He K; Yoo MH; Chan CB; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H; Fu H; Tao H; Ramalingam SS; Sun SY; Mischel PS; Ye K
J Biol Chem; 2012 Feb; 287(9):6113-27. PubMed ID: 22215664
[TBL] [Abstract][Full Text] [Related]
13. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
15. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
18. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
[TBL] [Abstract][Full Text] [Related]
19. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
